Today: 9 June 2026
3M stock price today: MMM steadies after earnings slide as tariff risk clouds 2026 outlook
21 January 2026
2 mins read

3M stock price today: MMM steadies after earnings slide as tariff risk clouds 2026 outlook

New York, January 21, 2026, 11:56 EST — Regular session

  • 3M shares climbed in mid-session trading, rebounding from Tuesday’s steep post-earnings slide
  • Investors are balancing 2026 profit forecasts with shifting consumer demand
  • Tariff uncertainty now takes center stage in discussions about near-term margins

3M shares climbed 0.7% to $157.26 in late morning trading Wednesday, recovering some ground after the sharp drop the day before as investors weighed the company’s 2026 forecast.

3M’s stock swing rippled through the Dow. Its $11.62 decline Tuesday was among the largest drags on the price-weighted index, which sank 888 points, according to MarketWatch data.

3M on Tuesday projected adjusted earnings for 2026 between $8.50 and $8.70 per share, with the midpoint falling a cent short of Wall Street’s forecast. The company flagged ongoing uneven demand. CEO Bill Brown noted that a current 20-cent-per-share tariff impact is already factored into those numbers. He added that potential new U.S. tariffs on eight European countries could trim $30 million to $40 million from 2026 earnings if imposed. Some consumer-facing segments, such as roofing granules and the automotive aftermarket, may remain under pressure early in the year. CFO Anurag Maheshwari told analysts he expects the “macro in 2026 to be a little bit better.” Reuters

Saint Paul, Minnesota-based 3M reported fourth-quarter adjusted earnings of $1.83 per share on roughly $6.0 billion in adjusted sales. The company posted 2.2% adjusted organic sales growth, which excludes currency fluctuations and acquisitions. Adjusted operating margin climbed to 21.1%. Looking ahead, 3M expects about 4% adjusted sales growth in 2026, with adjusted EPS between $8.50 and $8.70. “Our accelerated pace of innovation and commercial execution positions us to outperform the macro environment again in 2026,” said Brown. 3M Company

Adjusted results strip out some one-off items, and 3M still carries quite a few of those. The key question for investors: can pricing power and cost reductions continue to boost margins even as U.S. consumer spending slows?

The consumer segment, covering home and office goods, has lagged behind. A lackluster report in that area can overshadow solid industrial demand. Traders seemed unwilling to hang on for confirmation.

RBC Capital raised its price target to $136 from $131 on Wednesday but maintained an “Underperform” rating, citing ongoing consumer weakness and highlighting what it called “under-appreciated” risks linked to PFAS — the so-called “forever chemicals” involved in prolonged litigation. The gap between the target and current share price underscores the downside risk if tariff costs climb or legal bills spike again. Investing.com

If Washington follows through on its tariff threat, exporters such as 3M could face rapidly rising costs across their supply chains. The company’s current guidance factors in a baseline impact, but a bigger hit would challenge how much of those expenses it can shift onto customers.

Investors are eyeing February 1 as a key date, when President Donald Trump announced a 10% tariff would kick in on imports from Denmark, Norway, Sweden, France, Germany, the Netherlands, Finland, and Great Britain. For 3M, any official action before then—or indications the tariffs might be delayed or scrapped—could drive the next move in MMM shares.

Stock Market Today

  • Pro Portfolio Adds Broadcom and Netflix Shares, Upgrades Broadcom Rating
    June 9, 2026, 10:19 AM EDT. The Pro Portfolio is buying 80 shares of Broadcom (AVGO) at around $405, increasing its holdings to 512 shares (3.4% of the portfolio). It is also purchasing 372 shares of Netflix (NFLX) near $82.35, increasing its stake to 2,107 shares (2.85%). Broadcom's AI chip forecast for H2 2026 is viewed as conservative following a $35 billion private credit deal involving Apollo and Blackstone. The rating for Broadcom is upgraded to One, with a checkpoint price of $330 maintained. Netflix's shares are seen as undervalued despite recent declines, supported by a $25 billion buyback and rising U.S. viewership. Netflix's ad business shows growth potential, reaching 250 million monthly active viewers, reinforcing optimism amidst concerns over consumer spending.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Energy Fuels (UUUU) stock jumps premarket as $300 million ASM deal puts rare-earth supply chain in focus
Previous Story

Energy Fuels (UUUU) stock jumps premarket as $300 million ASM deal puts rare-earth supply chain in focus

P&G stock slips as earnings near; what PG investors watch on Thursday
Next Story

P&G stock slips as earnings near; what PG investors watch on Thursday

Go toTop